Cadila Healthcare Ltd has announced that the manufacturing facility of Alidac Pharmaceuticals Ltd (Alidac), located at Pharmez, Ahmedabad has received an Establishment Inspection Report (EIR). Alidac is a 100% subsidiary of Cadila Healthcare Ltd.
The USFDA had conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac, the injectable onco manufacturing facility, from 18th to 26th March, 2019. There was also a separate in—vitro BE inspection conducted by the Office of Study Integrity and Surveillance branch of the USFDA for the same product.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.245.3 as compared to the previous close of Rs. 246.1. The total number of shares traded during the day was 78040 in over 1592 trades.
The stock hit an intraday high of Rs. 248.4 and intraday low of 241.6. The net turnover during the day was Rs. 19140029.